The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Leading women's reproductive health conference directly follows the company's EU CE Mark approval for four of its products Leading women's reproductive health conference directly follows the company's...
Lee-Sepsick Discussed Company's FemCerv® Endocervical Tissue Sampler and its Role in Cervical Cancer Diagnosis Lee-Sepsick Discussed Company's FemCerv® Endocervical Tissue Sampler and its Role in Ce...
Lee-Sepsick Discussed Atlanta-Based Biomedical Company's Women's Reproductive Health Products Lee-Sepsick Discussed Atlanta-Based Biomedical Company's Women's Reproductive Health Products...
Femasys Inc. (FEMY) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago....
-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc ® for permanent non-surgical birth control continues -- ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- ...
Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting...
Femasys (FEMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-offi...
Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 Following FDA Clearance of FemaSeed®, Company Secures C...